Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Elevated clotting factor levels and venous thrombosis.

Rogier M Bertina1

  • 1Hemostasis and Thrombosis Research Center, Dept of Hematology, Leiden University Medical Center, Leiden, The Netherlands. R.M.Bertina@lumc.nl

Pathophysiology of Haemostasis and Thrombosis
|February 5, 2005
PubMed
Summary

Elevated levels of clotting factors like fibrinogen and prothrombin are linked to venous thromboembolism (VTE). Further research is needed to understand the molecular basis and improve thrombophilia screening.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis?

British journal of cancer·2016
Same author

Fibrinogen γ' increases the sensitivity to activated protein C in normal and factor V Leiden plasma.

Blood·2014
Same author

Procoagulant tissue factor activity on microparticles is associated with disease severity and bacteremia in febrile urinary tract infections.

Thrombosis research·2014
Same author

A novel serine protease secreted by medicinal maggots enhances plasminogen activator-induced fibrinolysis.

PloS one·2014
Same author

Cryo-electron microscopy of extracellular vesicles in fresh plasma.

Journal of extracellular vesicles·2014
Same author

Association of the thrombomodulin gene c.1418C>T polymorphism with thrombomodulin levels and with venous thrombosis risk.

Arteriosclerosis, thrombosis, and vascular biology·2013

Area of Science:

  • Hematology
  • Molecular Biology
  • Genetics

Background:

  • Several plasma proteins, including fibrinogen, factor VIII (FVIII), factor IX (FIX), factor XI (FXI), and prothrombin, are identified as independent risk factors for venous thromboembolism (VTE).
  • Limited understanding exists regarding the molecular mechanisms underlying these elevated plasma protein phenotypes.
  • Potential clustering of these phenotypes suggests shared pathways in their biosynthesis or clearance, warranting further investigation.

Purpose of the Study:

  • To explore the molecular basis of elevated plasma levels of key coagulation factors associated with VTE.
  • To investigate potential common pathways involved in the biosynthesis or clearance of these factors.
  • To address uncertainties in defining elevated plasma levels and the lack of confirmatory studies for certain factors (FIX, FXI) to facilitate their incorporation into thrombophilia screening.

Related Experiment Videos

Main Methods:

  • Analysis of plasma protein levels and their correlation with VTE risk.
  • Investigating genetic and molecular factors influencing protein biosynthesis and clearance.
  • Review of existing literature and prospective studies on coagulation factor levels and VTE.

Main Results:

  • Confirmed association between increased plasma levels of fibrinogen, FVIII, FIX, FXI, and prothrombin and VTE risk.
  • Identified gaps in knowledge regarding the molecular underpinnings of these observed plasma phenotypes.
  • Highlighted inconsistencies in defining elevated levels and the need for more robust data for FIX and FXI.

Conclusions:

  • While certain plasma protein levels are established VTE risk factors, their molecular basis remains incompletely understood.
  • Further research into shared biosynthetic or clearance pathways could elucidate phenotype clustering.
  • Clarifying diagnostic cut-offs and conducting prospective studies are crucial for integrating these markers into clinical thrombophilia screening.